Skip to content

Biosimilars Review & Report

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Biosimilar Approval Status
Home
- Home
About BR&R
News and Commentary
BR&R Manufacturer Profiles
- Amneal Biosciences
- Samsung Bioepis
Contact Us

$0.00 0 items

Alex_Azar_official_photo

Stanton Mehr February 1, 2019

Published by Stanton Mehr

View all posts by Stanton Mehr

Published February 1, 2019

Post navigation

Previous Post Secretary Azar Announces Plan to Remove Safe Harbor Protection for Drug Rebates

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Search for:

Recent Posts

Pharmacy’s View on MFN, MFP, and Drinking From the Firehouse April 17, 2026
100% Tariffs Slapped on Pharmaceutical Companies, With Many Exceptions: Circumventing the Supreme Court? April 3, 2026
FDA vs. EMA Biosimilar Approvals, an Update March 30, 2026
Samsung Bioepis, Sandoz Forge Deeper Biosimilar Ties March 19, 2026
As Oncology Biosimilar Acquisition Prices Fall for Hospitals, Biosimilar Adoption Rises March 16, 2026
The FDA’s New Draft Guidance Contributes to Streamlined Biosimilar Development March 12, 2026
Two Leaders’ Views on National PBM Reform: Biosimilar and ERISA Benefits March 9, 2026
Deeper Views on TrumpRx (the Direct-to-Patient Channel), MFN and MFP, and Biosimilars March 5, 2026
A Filgrastim Biosimilar Approval, and a Bevacizumab Rejection February 27, 2026
Will National PBM Reform Whither Away the Private-Label Channel? February 23, 2026

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Recent Comments

	Drug Manufacturers’… on The Inflation Reduction Act: R…
	Drug Manufacturers’… on Thirty Years of Exclusivity fo…
	Manjiri Kulkarni on What is Cordavis and Why Will…
	MK on Where’s Pfizer’s Adalimumab Bi…
	Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Top Posts & Pages

The Evolution of the Biosimilars Market
Biosimilar Bytes: Sandoz's Agreement and Organon/Henlius' Approval
Availability of Top Ranibizumab Biosimilar May be Paused
The Implications of the Freefall in Ranibizumab ASPs
Partners Amneal and Kashiv File 351(k) Application for Omalizumab Biosimilar
Phase 3 Trials Already Being Reconsidered by Manufacturers for Keytruda and Opdivo Biosimilars
Samsung Bioepis Manufacturer Profile Page FINAL
Biosimilar Bytes This Week
What is Cordavis and Why Will It Be Important to CVS Health and Biosimilars?
Biosimilar Approval Status

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.

To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

X
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions
Privacy Policy

Copyright

Copyright 2013-2026 by SM Health Communications LLC. All Rights Reserved

Powered by WordPress.com.